

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version  
2.17

Revision Date:  
14.04.2025

SDS Number:  
26444-00029

Date of last issue: 28.09.2024  
Date of first issue: 29.10.2014

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Golimumab Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-  
stance/Mixture : Pharmaceutical

Recommended restrictions  
on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Kilsheelan  
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person  
responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Respiratory sensitisation, Category 1 H334: May cause allergy or asthma symptoms or breathing difficulties if inhaled.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Danger

Hazard statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version  
2.17

Revision Date:  
14.04.2025

SDS Number:  
26444-00029

Date of last issue: 28.09.2024  
Date of first issue: 29.10.2014

---

Precautionary statements

: **Response:**

P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.  
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.

Hazardous components which must be listed on the label:

Golimumab

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

---

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Golimumab	476181-74-5	Resp. Sens. 1; H334	>= 10 - < 20

For explanation of abbreviations see section 16.

---

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version  
2.17

Revision Date:  
14.04.2025

SDS Number:  
26444-00029

Date of last issue: 28.09.2024  
Date of first issue: 29.10.2014

---

when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.  
If not breathing, give artificial respiration.  
If breathing is difficult, give oxygen.  
Get medical attention.

In case of skin contact : Wash with water and soap as a precaution.  
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

### 4.2 Most important symptoms and effects, both acute and delayed

Risks : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).  
  
May cause allergy or asthma symptoms or breathing difficulties if inhaled.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

---

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Sulphur oxides

### 5.3 Advice for firefighters

Special protective equipment : In the event of fire, wear self-contained breathing apparatus.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version 2.17	Revision Date: 14.04.2025	SDS Number: 26444-00029	Date of last issue: 28.09.2024 Date of first issue: 29.10.2014
-----------------	------------------------------	----------------------------	---

for firefighters	Use personal protective equipment.
Specific extinguishing methods	: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

## SECTION 6: Accidental release measures

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
----------------------	--

### 6.2 Environmental precautions

Environmental precautions	: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
---------------------------	--

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up	: Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.
-------------------------	---

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: Use only with adequate ventilation.
Advice on safe handling	: Do not breathe mist or vapours.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version Revision Date: SDS Number: Date of last issue: 28.09.2024  
2.17 14.04.2025 26444-00029 Date of first issue: 29.10.2014

- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
- Keep container tightly closed.
- Already sensitised individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitisers.
- Take care to prevent spills, waste and minimize release to the environment.
- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

## 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents  
Gases

### 7.3 Specific end use(s)

Specific use(s) : No data available

## **SECTION 8: Exposure controls/personal protection**

## 8.1 Control parameters

## Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Golimumab	476181-74-5	TWA	70 µg/m <sup>3</sup> (OEB 3)	Internal

## 8.2 Exposure controls

## Engineering measures

Ensure adequate ventilation, especially in confined areas.  
Minimize workplace exposure concentrations.

## Personal protective equipment

Eye/face protection : Wear the following personal protective equipment:  
Safety glasses  
Equipment should conform to NS EN 166

Hand protection

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version 2.17	Revision Date: 14.04.2025	SDS Number: 26444-00029	Date of last issue: 28.09.2024 Date of first issue: 29.10.2014
-----------------	------------------------------	----------------------------	---

Material	: Chemical-resistant gloves
Remarks	: Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.
Skin and body protection	: Skin should be washed after contact.
Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to NS EN 143
Filter type	: Particulates type (P)

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Physical state	: Aqueous solution
Colour	: opalescent
Odour	: No data available
Odour Threshold	: No data available
Melting point/freezing point	: No data available
Initial boiling point and boiling range	: No data available
Flammability (solid, gas)	: Not applicable
Flammability (liquids)	: No data available
Upper explosion limit / Upper flammability limit	: No data available
Lower explosion limit / Lower flammability limit	: No data available
Flash point	: No data available
Auto-ignition temperature	: No data available
Decomposition temperature	: No data available
pH	: 5,5

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version 2.17	Revision Date: 14.04.2025	SDS Number: 26444-00029	Date of last issue: 28.09.2024 Date of first issue: 29.10.2014
-----------------	------------------------------	----------------------------	---

---

Viscosity  
Viscosity, kinematic : No data available

Solubility(ies)  
Water solubility : soluble

Partition coefficient: n-octanol/water : No data available

Vapour pressure : No data available

Relative density : No data available

Relative vapour density : No data available

Particle characteristics  
Particle size : No data available

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions : Can react with strong oxidizing agents.

### 10.4 Conditions to avoid

Conditions to avoid : None known.

### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version 2.17	Revision Date: 14.04.2025	SDS Number: 26444-00029	Date of last issue: 28.09.2024 Date of first issue: 29.10.2014
-----------------	------------------------------	----------------------------	---

---

### SECTION 11: Toxicological information

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

##### Acute toxicity

Not classified based on available information.

##### Skin corrosion/irritation

Not classified based on available information.

##### Serious eye damage/eye irritation

Not classified based on available information.

##### Respiratory or skin sensitisation

###### Skin sensitisation

Not classified based on available information.

###### Respiratory sensitisation

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

##### Components:

###### Golimumab:

Exposure routes : Inhalation  
Assessment : May cause sensitisation by inhalation.

##### Germ cell mutagenicity

Not classified based on available information.

##### Carcinogenicity

Not classified based on available information.

##### Reproductive toxicity

Not classified based on available information.

##### Components:

###### Golimumab:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Mouse, male  
Application Route: Intravenous injection  
Fertility: NOAEL Parent: 40 mg/kg body weight

Test Type: Fertility/early embryonic development  
Species: Mouse, female  
Application Route: Intravenous injection  
Fertility: NOAEL Parent: 40 mg/kg body weight

Effects on foetal development : Test Type: Embryo-foetal development

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version 2.17	Revision Date: 14.04.2025	SDS Number: 26444-00029	Date of last issue: 28.09.2024 Date of first issue: 29.10.2014
-----------------	------------------------------	----------------------------	---

ment	Species: Monkey Teratogenicity: NOAEL: 100 mg/kg body weight Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight
	Test Type: Development Species: Monkey Developmental Toxicity: NOAEL F1: 50 mg/kg body weight
	Test Type: Embryo-foetal development Species: Mouse Application Route: Intravenous injection Teratogenicity: NOAEL: 40 mg/kg body weight Embryo-foetal toxicity: NOAEL: 40 mg/kg body weight Result: negative, No effects on foetal development

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

Not classified based on available information.

### Repeated dose toxicity

#### Components:

#### **Golimumab:**

Species	:	Monkey
NOAEL	:	50 mg/kg
Application Route	:	Intravenous
Exposure time	:	6 Months
Number of exposures	:	Intermittent
Species	:	Monkey
NOAEL	:	25 mg/kg
Application Route	:	Subcutaneous
Exposure time	:	6 Months
Species	:	Mouse
NOAEL	:	40 mg/kg
Application Route	:	Intravenous

### Aspiration toxicity

Not classified based on available information.

## 11.2 Information on other hazards

### **Endocrine disrupting properties**

Not classified based on available information.

#### Product:

Assessment	:	The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation
------------	---	--

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version  
2.17

Revision Date:  
14.04.2025

SDS Number:  
26444-00029

Date of last issue: 28.09.2024  
Date of first issue: 29.10.2014

---

(EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### Experience with human exposure

#### Components:

##### **Golimumab:**

Inhalation : Symptoms: mild infections, upper respiratory tract infection, viral infections, bronchitis, sinusitis, fungal infections

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### Components:

##### **Golimumab:**

#### **Ecotoxicology Assessment**

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

### 12.2 Persistence and degradability

No data available

### 12.3 Bioaccumulative potential

No data available

### 12.4 Mobility in soil

No data available

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version  
2.17

Revision Date:  
14.04.2025

SDS Number:  
26444-00029

Date of last issue: 28.09.2024  
Date of first issue: 29.10.2014

---

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number or ID number

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

### 14.2 UN proper shipping name

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good
RID	: Not regulated as a dangerous good
IMDG	: Not regulated as a dangerous good
IATA	: Not regulated as a dangerous good

### 14.4 Packing group

ADN	: Not regulated as a dangerous good
ADR	: Not regulated as a dangerous good

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version 2.17	Revision Date: 14.04.2025	SDS Number: 26444-00029	Date of last issue: 28.09.2024 Date of first issue: 29.10.2014
-----------------	------------------------------	----------------------------	---

<b>RID</b>	:	Not regulated as a dangerous good
<b>IMDG</b>	:	Not regulated as a dangerous good
<b>IATA (Cargo)</b>	:	Not regulated as a dangerous good
<b>IATA (Passenger)</b>	:	Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Conditions of restriction for the following entries should be considered: Number on list 3
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or not.
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable
Regulation (EU) No 2024/590 on substances that deplete the ozone layer	:	Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast)	:	Not applicable
Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals	:	Not applicable
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.	:	Not applicable
		Not applicable

### Other regulations:

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version  
2.17

Revision Date:  
14.04.2025

SDS Number:  
26444-00029

Date of last issue: 28.09.2024  
Date of first issue: 29.10.2014

### The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H334 : May cause allergy or asthma symptoms or breathing difficulties if inhaled.

### Full text of other abbreviations

Resp. Sens. : Respiratory sensitisation

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI -

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Golimumab Formulation

Version  
2.17

Revision Date:  
14.04.2025

SDS Number:  
26444-00029

Date of last issue: 28.09.2024  
Date of first issue: 29.10.2014

---

Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

Resp. Sens. 1

H334

### Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN